Infisign Showcases Successful Interoperability for Verifiable Credential Issuance and Verification

Key Highlights:
- At JFF PlugFest, Infisign showcased various verifiable credentials, including an OBv3 badge and a USCIS document, with detailed issuer and achievement information.
- The platform processed requests efficiently, enabling users to select credentials for presentation.
- Using the OIDC4VCI protocol, Infisign issued credentials, while OIDC4VP facilitated their verification.
- The system supported selective attribute disclosure, ensuring privacy.
- This was exemplified in a use case where multiple credentials were issued and verified, requiring specific attributes from each, which could be securely shared through Infisign's wallet.
"Infisign remains steadfast in its mission to provide secure and privacy-centric identity management solutions and this success at PlugFest 3 affirms our progress and the value we bring to the IAM sector," added
About Infisign
Infisign specializes in Identity and Access Management solutions, focusing on Zero Trust Protocols and Zero Knowledge Proofs for passwordless authentication. The company provides Single Sign-On (SSO), Passwordless, and Privileged Access Management (PAM) capabilities, and a comprehensive solution for employee lifecycle management.
For more information, please visit www.infisign.io
Press Contact:
Kapildev Arulmozhi
CMSO
[email protected]
+1 646 760 9857
For more details on JFF PlugFest 3, please visit W3C PlugFest 3 Participants.
Logo: https://mma.prnewswire.com/media/2148140/infisign_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/infisign-showcases-successful-interoperability-for-verifiable-credential-issuance-and-verification-301992008.html
SOURCE Infisign Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tata Elxsi delivers healthy revenue growth of 3.4% QoQ and 15% YoY in Q2 FY'27
- egnite's Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026
- Legacy Healthcare's CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share